Curis Inc (CRIS) stock
CRISNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/3091% below fair value
$0.61+0.07 (+13.38%)
Close on Nov 18, 2026Market cap $1.28MP/E –Yield –
Curis free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Curis's free cash flow for the twelve months ending Dec 31, 2023 was -$38.43M. For fiscal 2023 it was -$38.43M. The highest annual figure on record is -$1.90M in fiscal 2010.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$38.43M | – |
| FY2022 | Dec 31, 2022 | -$54.75M | – |
| FY2021 | Dec 31, 2021 | -$37.62M | – |
| FY2020 | Dec 31, 2020 | -$26.42M | – |
| FY2019 | Dec 31, 2019 | -$26.25M | – |
| FY2018 | Dec 31, 2018 | -$30.15M | – |
| FY2017 | Dec 31, 2017 | -$48.54M | – |
| FY2016 | Dec 31, 2016 | -$36.14M | – |
| FY2015 | Dec 31, 2015 | -$29.94M | – |
| FY2014 | Dec 31, 2014 | -$16.91M | – |
| FY2013 | Dec 31, 2013 | -$9.69M | – |
| FY2012 | Dec 31, 2012 | -$15.30M | – |
| FY2011 | Dec 31, 2011 | -$4.82M | – |
| FY2010 | Dec 31, 2010 | -$1.90M | – |
| FY2009 | Dec 31, 2009 | -$7.61M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | -$10.19M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.18M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.87M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.20M | – |
| Q4 FY2022 | Dec 31, 2022 | -$12.27M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.17M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.49M | – |
| Q1 FY2022 | Mar 31, 2022 | -$16.83M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.17M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.61M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.66M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.18M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.74M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.04M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.39M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.26M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.60M | – |
| Q3 FY2019 | Sep 30, 2019 | -$6.70M | – |
| Q2 FY2019 | Jun 30, 2019 | -$6.71M | – |
| Q1 FY2019 | Mar 31, 2019 | -$7.23M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.94M | – |
| Q3 FY2018 | Sep 30, 2018 | -$8.23M | – |
| Q2 FY2018 | Jun 30, 2018 | -$6.94M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.04M | – |
| Q4 FY2017 | Dec 31, 2017 | -$7.55M | – |
| Q3 FY2017 | Sep 30, 2017 | -$16.50M | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.30M | – |
| Q1 FY2017 | Mar 31, 2017 | -$15.20M | – |
| Q4 FY2016 | Dec 31, 2016 | -$9.45M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.60M | – |
See a number that looks wrong?